^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    everolimus

    i
    Other names: RAD, RAD001, SDZ RAD, RAD 001, RAD-001
    Company:
    Generic mfg.
    Drug class:
    mTOR inhibitor
    Related drugs:
    15h
    A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. (clinicaltrials.gov)
    P3, N=400, Recruiting, Pfizer
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    everolimus • fulvestrant • exemestane • prifetrastat (PF-07248144)
    16h
    The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy (clinicaltrials.gov)
    P1, N=5, Recruiting, Xuanwu Hospital, Beijing | Initiation date: Mar 2026 --> Jul 2026
    Trial initiation date
    |
    everolimus
    18h
    RapaLoad: Everolimus and/or Exercise to Prevent Bone Loss in Postmenopausal Women (clinicaltrials.gov)
    P2, N=136, Active, not recruiting, Odense University Hospital | Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Oct 2026 | Trial primary completion date: Jul 2025 --> Mar 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    everolimus
    18h
    LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy (clinicaltrials.gov)
    P1/2, N=12, Completed, Georgetown University | N=44 --> 12 | Active, not recruiting --> Completed
    Trial completion • Enrollment change
    |
    everolimus • Kisqali (ribociclib)
    2d
    StrongBone: Resistance Training and Rapamycin to Enhance Bone Formation in Postmenopausal Women (clinicaltrials.gov)
    P2, N=148, Recruiting, Odense University Hospital | Not yet recruiting --> Recruiting
    Enrollment open • Trial initiation date
    |
    everolimus • sirolimus
    2d
    EVERO Drug-coated Balloon (DCB) Randomized Trial (clinicaltrials.gov)
    P=N/A, N=410, Recruiting, Cook Research Incorporated | Not yet recruiting --> Recruiting
    Enrollment open
    |
    everolimus
    2d
    Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=26, Completed, Gustave Roussy, Cancer Campus, Grand Paris | Unknown status --> Completed
    Trial completion
    |
    everolimus
    3d
    Progress in management of advanced clear-cell renal cell carcinoma. (PubMed, Clin Transl Oncol)
    After prior ICI exposure, VEGFR-TKIs continue to represent the treatment backbone, while later-line options such as hypoxia-inducible factor-2α (HIF-2α) inhibitors and lenvatinib-everolimus further expand sequencing possibilities. Randomized studies have not shown consistent benefit for routine ICI rechallenge in unselected populations. Overall, advanced ccRCC management requires structured individualization, while validated predictive biomarkers and prospective sequencing data remain important unmet needs.
    Review • Journal • IO biomarker
    |
    EPAS1 (Endothelial PAS domain protein 1)
    |
    everolimus • Lenvima (lenvatinib)
    4d
    Everolimus destabilizes thymidylate synthase via suppressing its O-GlcNAcylation and sensitizes HER2-negative breast cancer to fluorouracil. (PubMed, Cell Death Dis)
    5-Fluorouracil (5-FU) and its prodrugs are widely used drugs for chemotherapy in various cancers. In conclusion, our study reveals that everolimus sensitizes breast cancer to fluoropyrimidines by destabilizing TYMS through modulation of its O-GlcNAcylation. These findings support a promising combination strategy to improve the therapeutic efficacy of 5-FU and capecitabine in breast cancer.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • TYMS (Thymidylate Synthetase) • OGT (O-linked N-acetylglucosamine (GlcNAc) transferase)
    |
    HER-2 negative
    |
    5-fluorouracil • everolimus • capecitabine
    6d
    Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study. (PubMed, ESMO Real World Data Digit Oncol)
    The most common regimens included capecitabine and everolimus plus exemestane. Multivariable analysis showed that younger age, prior fulvestrant use, and shorter CDK4/6i duration were associated with CHT choice...Treatment decisions are influenced by clinical history and patient characteristics. These findings underscore the need for personalized approaches and molecular profiling to guide post-CDK4/6i therapy in HR-positive/HER2-negative MBC.
    Journal • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • EGFR positive • HR positive + HER-2 negative
    |
    everolimus • capecitabine • fulvestrant • exemestane
    6d
    Role of Anti-GD2 Targeted PEG-b-PLGA Nanoparticles in the Treatment of MYCN Driven Neuroblastoma. (PubMed, ACS Appl Bio Mater)
    Everolimus (EVER) and tozasertib (TOZA) encapsulated in NP and targeted with dinutuximab β (DTX-β). DTX-β/EVER-TOZA@PEG-b-PLGA may exert cytotoxic and apoptotic effects in NB. The use of targeted nanocarriers in NB treatment may enhance cytotoxic and apoptotic responses specifically in the tumor region.
    Journal
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN expression
    |
    everolimus • Unituxin (dinutuximab) • tozasertib (MK-0457)
    6d
    FUSCC Refractory TNBC Platform Study (FUTURE2.0) (clinicaltrials.gov)
    P2, N=120, Recruiting, Fudan University
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    everolimus • AiRuiKa (camrelizumab) • trastuzumab rezetecan (SHR-A1811) • famitinib (SHR 1020)